Everett Harris & Co. CA Makes New Investment in Edwards Lifesciences Corporation $EW

Everett Harris & Co. CA purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, HoldingsChannel reports. The institutional investor purchased 80,341 shares of the medical research company’s stock, valued at approximately $7,268,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EW. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $25,000. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences during the first quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences in the fourth quarter worth approximately $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of recent research reports. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Robert W. Baird upped their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Citigroup boosted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Truist Financial increased their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Price Performance

NYSE:EW opened at $91.51 on Friday. The business’s 50-day simple moving average is $88.73 and its two-hundred day simple moving average is $84.37. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The stock has a market cap of $52.69 billion, a PE ratio of 52.59, a P/E/G ratio of 2.32 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 26,190 shares of company stock valued at $2,269,697. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.